Day: July 10, 2024

Phase 1 HELIOS study evaluates AXPAXLI™ for non-proliferative diabetic retinopathy (NPDR) BEDFORD, Mass., July 10, 2024 (GLOBE NEWSWIRE) — Ocular Therapeutix, Inc. (NASDAQ: OCUL, “Ocular”, the “Company”), a biopharmaceutical company committed to enhancing people’s vision and quality of life through the development and commercialization of innovative therapies for wet age-related macular degeneration (wet AMD), diabetic retinopathy, and other diseases and conditions of the eye, today announced that a late-breaking abstract related to the Phase 1 HELIOS study of AXPAXLI (axitinib intravitreal implant) for non-proliferative diabetic retinopathy (NPDR) was accepted for presentation at the 42nd American Society of Retina Specialists (ASRS) Annual Scientific Meeting being held July 17-20 in Stockholm, Sweden. Presentation at ASRS...

VANCOUVER, British Columbia, July 10, 2024 (GLOBE NEWSWIRE) — Greenridge Exploration Inc. (“Greenridge” or the “Company”) (CSE: GXP | FRA: HW3), is pleased to announce it has undertaken an extensive summer exploration work program (the “Program”) on its Carpenter Lake Project (the “Carpenter Lake Project” or the “Project”) located on the southern margin of the Athabasca Basin, Saskatchewan. 2024 Summer Exploration Work Program On behalf of Greenridge, Dahrouge Geological Consulting Ltd. (“DGC”) is conducting a fourteen-day large-scale Program on the Company’s Carpenter Lake Project which includes:Detailed geological mapping in highly prospective target areas; Prospecting and rock sampling over priority target areas; and Scintillometer sweeps over priority areas that are lacking outcrop.Figure 1: Carpenter Lake Uranium Project...

Formulation designed to enhance brain uptake SARASOTA, Fla., July 10, 2024 (GLOBE NEWSWIRE) — Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced it has developed a new formulation for its novel neurosteroid. Oragenics’ lead drug candidate for concussion, ONP-002, is a new chemical entity (NCE) designed to target the brain through delivery into the nasal cavity and onward to the brain. A Phase II study in concussed patients is being planned to assess safety and feasibility while analyzing the drug’s effectiveness based on patient blood biomarker profiles and functional outcomes. Oragenics believes the nasal cavity provides access for Oragenics’ novel neurosteroid formulation to enter the brain in minutes. Given the...

SAN DIEGO, July 10, 2024 (GLOBE NEWSWIRE) —  Genasys Inc. (NASDAQ: GNSS), the global leader in Protective Communications, today announced a new Genasys EVAC (EVAC) contract with Santa Barbara County. Santa Barbara joins 36 other California counties in deploying EVAC, a revolutionary, zone-based crisis response and alerting solution, to enhance the safety of residents and visitors during critical events. “EVAC has quickly become the crisis planning, evacuation modeling, and situational awareness solution of choice for first responders and emergency managers,” said Richard Danforth, CEO of Genasys. “EVAC accelerates decision making time by identifying areas for protective action, enhances communication and collaboration with agencies during cross jurisdictional events, integrates and displays zone-based maps on county and municipal...

Roseland, NJ, July 10, 2024 (GLOBE NEWSWIRE) — Gaxos.ai Inc. (“Gaxos” or the “Company”), a company developing artificial intelligence applications across various sectors, today announced that it partnered with Meshy to deliver 3D assets in its AI solution for game developers and publishers. “We are happy to announce our partnership with Meshy to deliver quality 3D models through our product,” said Vadim Mats, CEO of Gaxos.AI. “We look forward to working with Meshy to make our product and service and integral part of any game developer’s or publisher’s toolkit.” “We are thrilled to partner with Gaxos and bring our advanced 3D generative AI features to their users,” said Ethan Hu, CEO of Meshy. “This collaboration allows us to offer innovative tools that make it easier for game developers...

Sustained exposure to OV329 in preclinical models reduced GABA-aminotransferase (GABA-AT) activity, increased steady state GABA levels in the brain, and induced phasic and tonic inhibition OV329 demonstrated anti-convulsant effects in mice, reducing the severity of status epilepticus and preventing the development of benzodiazepine-resistant seizures OV329 was shown to have a higher potency (as measured by IC50) for the GABA-AT target than published studies of vigabatrin, an FDA-approved GABA-AT inhibitorNEW YORK, July 10, 2024 (GLOBE NEWSWIRE) — Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to improving the lives of people affected by rare epilepsies and brain conditions, announced that eNeuro, a peer-reviewed, open-access journal from the Society for Neuroscience published several preclinical...

Ongoing Phase 1 study informed dose selection for CARGO’s currently enrolling, potentially pivotal Phase 2 clinical study, FIRCE-1 of firicabtagene autoleucel (firi-cel)1, in patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) Notable patient subset analyses show durability of Complete Response (CR), underscoring promising efficacy in a high-risk, heavily pretreated population with advanced disease Most recent, longer-term follow-up data for Stanford Medicine’s Phase 1 presented at the 2024 European Hematology Association (EHA) Congress, continued to show promising efficacy, durability and safety profile of firi-celSAN CARLOS, Calif., July 10, 2024 (GLOBE NEWSWIRE) — CARGO Therapeutics, Inc. (Nasdaq: CRGX), a clinical-stage biotechnology company positioned to advance next generation, potentially curative...

Revenues reach new all time record SAN DIEGO, CALIFORNIA, July 10, 2024 (GLOBE NEWSWIRE) — International Land Alliance, Inc. (OTCQB:ILAL), (“ILAL” or the “Company”), an international land investment and development firm, reported results for the first quarter ended March 31, 2024. Q1 2024 HighlightsQuarterly sales volume of $5.1 million Net Income of $3.7 million or $0.05 per diluted share Total Assets increased to $30.4 million Current Assets increased to $1.7 million Total stockholders’ equity increased to $14.4 millionFrank Ingrande, ILAL’s President and CEO, commented: We are happy to have delivered record revenue and profitability last quarter. Our strategic growth initiatives as well as focusing on operational and financial efficiencies have driven this improved performance. Furthermore, the adopted efficiencies and revenue...

REDWOOD CITY, Calif., July 10, 2024 (GLOBE NEWSWIRE) — Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company pioneering the use of gene therapy as a new standard of care for highly prevalent ocular diseases, today announced that the company will host a webcast to review the interim 26-week landmark data from its ongoing LUNA Phase 2 study of ixoberogene soroparvovec (Ixo-vec) for the treatment of wet age-related macular degeneration (wet AMD) being presented at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting. The webcast will be held on Wednesday, July 17 at 8:00 a.m. ET and will include a presentation from Dr. Charles C. Wykoff, Director of Research, Retina Consultants of Texas, Professor of Clinical Ophthalmology, Blanton Eye Institute, Houston Methodist Hospital, and principal investigator...